Trial Profile
A Single Center Study Evaluating Safety and Efficacy Of Bortezomib In Combination With High Dose Melphalan As Conditioning Regimen Before Autologous Stem Cell Transplantation In Newly Diagnosed Multiple Myeloma Patients.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Jan 2017
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone; Melphalan; Thalidomide
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 20 Jan 2017 New trial record
- 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.